Commencement of FebriDx CLIA Waiver Study
Filed with ASX · · 3 pages · English
Watch Lumos Diagnostics' latest callLumos Diagnostics Holdings (ASX:LDX) Q3 2026 Earnings Call · Replay · Apr 20Read the transcript of Lumos Diagnostics Holdings (ASX:LDX) Q3 2026 Earnings CallLumos Diagnostics Holdings Ltd. on 6ix
Story so far
Earlier from Lumos Diagnostics
- Lumos receives CPT PLA Code for FebriDX in the US
- Lumos Successfully Completes Retail Entitlement Offer
- Lumos and BARDA Partner to Support FebriDx CLIA Waiver Study
- Lumos Awarded National Contract with MediGroup for FebriDx
- Lumos Achieves First Phase 2 Milestone in Hologic Agreement
Later from Lumos Diagnostics
- Hologic Development Agreement Expanded Scope of Works
- Lumos Secures Key US Reimbursement Milestones for FebriDx
- Lumos Secures Further US Medicare Reimbursement for FebriDx
- Lumos Advances FebriDx Sales with iMedical Purchase Order
- Lumos Secures Fifth US Medicare Reimbursement for FebriDx
Follow Lumos Diagnostics into a list and get an email when it puts out news.
Follow Lumos Diagnostics